Pain Management Market is anticipated to register a CAGR of 7.39% during 2023 - 2028 - Market Size, Share, Forecasts, and Trends Analysis Report by Mordor Intelligence.
31 mars 2023 09h00 HE
|
Mordor Intelligence
Hyderabad, March 31, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Pain Management Market - (2023 – 2028),” the market is expected to register a CAGR of 7.39%. The...
Flow Diverters Market to Hit $1.04 Billion, with CAGR of 15.3% by 2031: Allied Market Research
27 nov. 2022 19h00 HE
|
Allied Market Research
Portland, OR, Nov. 27, 2022 (GLOBE NEWSWIRE) -- A new business intelligence report released by Allied Market Research, the global Flow Diverters Market generated $251.50 million in 2021, and is...
Arch Therapeutics Novel Self-Assembling Agent, AC5-GTM, for Use in Endoscopic Procedures was Presented at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2020 Annual Meeting
11 août 2020 08h01 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics to Provide Corporate Update at the 2019 BIO CEO & Investor Conference
05 févr. 2019 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Arch Therapeutics to Provide Corporate Update at the 11th Annual Biotech Showcase™ 2019 Conference on January 8th, 2019
20 déc. 2018 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Arch Therapeutics Receives 510(k) Clearance from the US FDA for AC5™ Topical Gel
17 déc. 2018 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics Provided Corporate Update at the 11th Annual LD Micro Main Event
06 déc. 2018 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics Announces Positive Outcome of Ruling from Japanese Intellectual Property High Court
04 déc. 2018 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is...
Arch Therapeutics Announces Submission of CE Mark File for AC5™ Topical Hemostat in Europe
28 nov. 2018 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Nov. 28, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Minerva Announces Amended Agreement for MIN-202 in Insomnia
31 mai 2017 16h05 HE
|
Minerva Neurosciences, Inc.
Minerva to gain global strategic control over development of MIN-202 for insomnia Janssen cash payments to Minerva of up to $70 million, including $30 million upfront All shares in Minerva held by...